293 cells were transfected with anti-MSLN-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-Labeled Human Mesothelin (296-580), Fc Tag (Cat. No. MSN-HF25x, 0.3 µg/ml) and C. FITC-labeled protein control. A. Non-transfected 293 cells and C. FITC-labeled protein control were used as negative control. RFP was used to evaluate CAR (anti-MSLN-scFv) expression and FITC was used to evaluate the binding activity of FITC-Labeled Human Mesothelin (296-580), Fc Tag (Cat. No. MSN-HF25x).
Anti-human MSLN MAb (chimeric mouse-human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface, can bind RFP Fusion Human Mesothelin (296-580), His Tag (Cat. No. MSN-HR2P4) with an affinity constant of 0.304 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Anti-human MSLN MAb (chimeric mouse-human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface, can bind GFP Fusion Human Mesothelin (296-580), His Tag (Cat. No. MSN-HG2P4) with an affinity constant of 0.542 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| RG-7600 | DMOT-4039A; RG-7600 | Phase Ⅰ | Genentech | Ovarian cancer, Pancreatic cancer | Details |
| CART-meso | CART-meso | Phase Ⅰ | University of Pennsylvania, Novartis | Mesothelioma, Ovarian cancer, Pancreatic cancer | Details |
| MCY-M11 | MCY-M11 | Phase Ⅰ | MaxCyte | Pleural mesothelioma, Ovarian cancer | Details |
| CAT-5001 | CAT-5001 | Phase Ⅱ | National Cancer Institute, AstraZeneca | Mesothelioma, Ovarian cancer, Pancreatic cancer | Details |
| Anti-mesothelin CAR T cell therapy (Shanghai GeneChem) | Phase Ⅰ | Shanghai GeneChem | Pancreatic cancer | Details | |
| anti-mesothelin thorium-227 labeled antibody chelator conjugate | BAY-2287411 | Phase Ⅰ | Bayer | Solid tumours | Details |
| KD-021 (Nanjing KAEDI Biotech) | KD-021 | Phase Ⅰ | Nanjing KAEDI Biotech | Solid tumours | Details |
| Amatuximab | MORAb-009; MORAB-009-006 | Phase Ⅱ | National Cancer Institute, Morphotek | Mesothelioma, Solid tumours, Pancreatic cancer | Details |
| Anetumab ravtansine | BAY-94-9343; BAY-94-9343-SPDB-DM4; Anti-mesothelin antibody-drug conjugate BAY 94-9343 | Phase Ⅱ | Bayer, MorphoSys | Non small cell lung cancer (NSCLC), Mesothelioma, Solid tumours | Details |
| Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) | Phase Ⅱ | Shanghai Cell Therapy Research Institute | Solid tumours | Details | |
| LMB-100 | LMB-100; RG-7787; RO-6927005 | Phase Ⅱ | Roche, National Cancer Institute, Selecta Biosciences | Mesothelioma | Details |
| iCasp9M28z | iCasp9M28z | Phase Ⅰ | Memorial Sloan-Kettering Cancer Center | Pleural mesothelioma, Mesothelioma, Breast cancer, Lung cancer, Metastatic cancer | Details |
| BMS-986148 | BMS-986148 | Phase Ⅱ | Bristol-Myers Squibb | Solid tumours | Details |
| RNA-Meso-CIR-T | RNA-Meso-CIR-T | Phase Ⅰ | University of Pennsylvania, Novartis | Mesothelioma | Details |
| Anti-mesothelin CAR T-cell therapy (Marino Biotechnology) | Phase Ⅰ | Marino Biotechnology | Cancer | Details |
This web search service is supported by Google Inc.
A-Z
